Compare Bristol-Myers Squibb Co (BMY) vs Nuscale Power Corporation (SMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Nuscale Power Corporation — how do they compare? Bristol-Myers Squibb Co trades at $58.62 (market cap $116.30B), while Nuscale Power Corporation trades at $8.34 (market cap $2.98B). The key difference: Bristol-Myers Squibb Co is far larger — about 39× Nuscale Power Corporation's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Nuscale Power Corporation pays none. Which is the better fit depends on your goals.
| BMY | SMR | |
|---|---|---|
Market Cap | $116.30B | $2.98B |
Sector | Health | Utilities |
52-Week High | $62.37 | $53.43 |
52-Week Low | $42.60 | $8.36 |
Enterprise Value | $152.24B | $2.09B |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
NuScale Power (SMR) trades at $8.36, down 7.42% in the last session and near its 52-week low. The stock shows bearish technical signals with oversold RSI readings, while fundamentals reveal significant challenges including negative net income margins (-2,066.55%) and declining revenue projections. Recent news highlights the company's unique position as the only US company with certified small modular reactor design approval, though commercialization timelines remain uncertain.
Despite analyst consensus pointing to 46% upside potential with a $12.25 price target, SMR faces substantial execution risks. The company must demonstrate commercial viability of its reactor technology while managing cash burn. Long-term potential exists in nuclear energy's AI-driven demand surge, but near-term profitability remains elusive with projected losses through 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →
